Last reviewed · How we verify
Standard infliximab intravenous therapy
Standard infliximab intravenous therapy is a Small molecule drug developed by Asan Medical Center. It is currently FDA-approved. Also known as: Standard infliximab (CT-P13, RemsimaTM) intravenous therapy.
At a glance
| Generic name | Standard infliximab intravenous therapy |
|---|---|
| Also known as | Standard infliximab (CT-P13, RemsimaTM) intravenous therapy |
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
- Determination of the Optimal Treatment Target in Ulcerative Colitis (PHASE4)
- Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease (PHASE2)
- Vedolizumab in Pediatric Ulcerative Colitis- Comparison With Infliximab (PHASE3)
- TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's Disease (PHASE4)
- Infliximab in the Treatment of Patients With Severe COVID-19 Disease (PHASE2)
- Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard infliximab intravenous therapy CI brief — competitive landscape report
- Standard infliximab intravenous therapy updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about Standard infliximab intravenous therapy
What is Standard infliximab intravenous therapy?
Standard infliximab intravenous therapy is a Small molecule drug developed by Asan Medical Center.
Who makes Standard infliximab intravenous therapy?
Standard infliximab intravenous therapy is developed and marketed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).
Is Standard infliximab intravenous therapy also known as anything else?
Standard infliximab intravenous therapy is also known as Standard infliximab (CT-P13, RemsimaTM) intravenous therapy.
What development phase is Standard infliximab intravenous therapy in?
Standard infliximab intravenous therapy is FDA-approved (marketed).
Related
- Manufacturer: Asan Medical Center — full pipeline
- Also known as: Standard infliximab (CT-P13, RemsimaTM) intravenous therapy